Hemarus Therapeutics Profile
Key Indicators
- Authorised Capital ₹ 40.00 Cr
- Paid Up Capital ₹ 1.00 M
- Company Age 21 Year, 4 Months
- Last Filing with ROC 31 Mar 2022
- Satisfied Charges ₹ 75.40 Cr
- Revenue Growth -84.64%
- Profit Growth -275.80%
- Ebitda -716.81%
- Net Worth -73.64%
- Total Assets -87.88%
About Hemarus Therapeutics
Hemarus Therapeutics Limited (HTL) is a leading Public Limited Indian Non-Government Company incorporated in India on 16 September 2003 and has a history of 21 years and four months. Its registered office is in Hyderabad, Telangana, India.
The Corporate was formerly known as Hemarus Therapeutics Private Limited. The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 40.00 Cr and a paid-up capital of Rs 1.00 M.
The company has closed loans amounting to ₹75.40 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Talari Venkatesh, Satish Ganne, and Satish Saudam serve as directors at the Company.
Company Details
-
Location
Hyderabad, Telangana, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U74220TG2003PLC041698
-
Company No.
041698
-
Company Classification
Public Limited Indian Non-Government Company
-
Incorporation Date
16 Sep 2003
-
Date of AGM
29 Aug 2022
-
Date of Balance Sheet
31 Mar 2022
-
Listing Status
Unlisted
-
ROC Code
Roc Hyderabad
Industry
What products or services does Hemarus Therapeutics Limited offer?
Hemarus Therapeutics Limited offers a wide range of products and services, including Immunomodulator Drugs, Normal Immunoglobulin Injection, Medical Consultancy Services, Health Care Consultancy Service.
Who are the key members and board of directors at Hemarus Therapeutics?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Talari Venkatesh
|
Director | 06-Aug-2022 | Current |
|
Satish Ganne
|
Director | 03-Sep-2021 | Current |
|
Satish Saudam
|
Director | 30-Sep-2021 | Current |
Financial Performance of Hemarus Therapeutics.
Hemarus Therapeutics Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 84.64% decrease. The company also saw a substantial fall in profitability, with a 275.8% decrease in profit. The company's net worth observed a substantial decline by a decrease of 73.64%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Hemarus Therapeutics?
In 2022, Hemarus Therapeutics had a promoter holding of 90.54% and a public holding of 9.46%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0
₹75.40 Cr
Charges Breakdown by Lending Institutions
- Indian Overseas Bank : 66.68 Cr
- Andhra Pradesh State Financial Corporation : 8.72 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 26 Feb 2011 | Indian Overseas Bank | ₹66.68 Cr | Satisfied |
| 10 Aug 2004 | Andhra Pradesh State Financial Corporation | ₹8.72 Cr | Satisfied |
How Many Employees Work at Hemarus Therapeutics?
Hemarus Therapeutics has a workforce of 68 employees as of Mar 31, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Hemarus Therapeutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Hemarus Therapeutics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
